Actively Recruiting
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Led by Eli Lilly and Company · Updated on 2025-09-25
540
Participants Needed
49
Research Sites
297 weeks
Total Duration
On this page
Sponsors
E
Eli Lilly and Company
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
CONDITIONS
Official Title
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients have measurable disease according to RECIST v1.1 criteria.
- Disease must show evidence of KRAS G12C mutation in tumor tissue or circulating tumor DNA.
- Diagnosis of locally advanced, unresectable, or metastatic cancer confirmed by histology or cytology.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate organ function as determined by screening tests.
- Discontinued all prior cancer treatments with resolution of significant ongoing side effects, except in specified scenarios.
- Ability to swallow capsules or tablets.
- Agree to use contraception if applicable.
- For some study parts, untreated Stage IIIB-IIIC or IV non-small-cell lung cancer not suitable for curative surgery or radiation, with specific prior treatment conditions.
- For one study arm, prior treatment with at least one oxaliplatin- or irinotecan-containing regimen for advanced or metastatic colorectal cancer required.
You will not qualify if you...
- Disease suitable for local therapy with curative intent.
- Active, ongoing, or untreated infections.
- Serious pre-existing medical conditions that may prevent participation.
- Serious cardiac conditions.
- Second active primary cancer or cancer diagnosed/treated within 3 years before enrollment.
- Untreated active central nervous system metastases or leptomeningeal disease for some study parts; treated CNS metastases allowed if stable and asymptomatic.
- Prior treatment with any KRAS G12C small molecule inhibitor except as allowed by protocol.
- Certain serious side effects from prior immunotherapy for some study parts.
- Active autoimmune disease requiring systemic treatment in past 2 years.
- Received live vaccine within 30 days before first study drug dose.
- Pregnant, breastfeeding, or planning pregnancy through 35 days after last dose.
- Known allergy to any study treatment components.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 49 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
USC Norris Cancer Hospital
Los Angeles, California, United States, 90033
Actively Recruiting
3
Chao Family Comprehensive Cancer Ctr.
Orange, California, United States, 92868
Actively Recruiting
4
Yale-New Haven Hospital
New Haven, Connecticut, United States, 06510
Actively Recruiting
5
AdventHealth Orlando
Orlando, Florida, United States, 32803
Actively Recruiting
6
Florida Cancer Specialists
Sarasota, Florida, United States, 34236
Actively Recruiting
7
Indiana Univ Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Actively Recruiting
8
Community Health Network
Indianapolis, Indiana, United States, 46250
Actively Recruiting
9
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States, 70809
Actively Recruiting
10
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
11
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
12
NYU Langone Health- Long Island
Mineola, New York, United States, 11501
Actively Recruiting
13
NYU Langone
New York, New York, United States, 10016
Actively Recruiting
14
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
15
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
16
Novant Health Cancer Institute - Elizabeth
Charlotte, North Carolina, United States, 28204
Actively Recruiting
17
Novant Health Cancer Institute - Forsyth
Winston-Salem, North Carolina, United States, 27103
Actively Recruiting
18
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111-2497
Actively Recruiting
19
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
20
Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203
Actively Recruiting
21
Vanderbilt Univeristy School of Medicine
Nashville, Tennessee, United States, 37212-6303
Actively Recruiting
22
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States, 78229-3307
Actively Recruiting
23
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
24
Inova Health System IRB
Fairfax, Virginia, United States, 22031
Actively Recruiting
25
USO-Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
Actively Recruiting
26
University of Wisconsin-Madison Hospital and Health Clinic
Madison, Wisconsin, United States, 53792-4108
Actively Recruiting
27
Royal North Shore Hospital
St Leonards, New South Wales, Australia, 2065
Actively Recruiting
28
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia, 2010
Actively Recruiting
29
Cancer Research SA
Adelaide, South Australia, Australia, 5000
Actively Recruiting
30
Peninsula and Southeast Oncology
Frankston, Victoria, Australia, 3199
Actively Recruiting
31
Linear Clinical Research
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
32
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
33
Princess Margaret Hospital (Ontario)
Toronto, Ontario, Canada, M4X 1K9
Actively Recruiting
34
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, Aquitaine, France, 33076
Actively Recruiting
35
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France, 69008
Actively Recruiting
36
Institut du Cancer de Montpellier - Val d'aurelle
Montpellier, France, 34298
Actively Recruiting
37
Institut Claudius Regaud - IUCT Oncopole
Toulouse, France, 31052
Actively Recruiting
38
Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
39
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan, 464-8681
Actively Recruiting
40
National Cancer Center Hospital East
Kashiwa, Chiba, Japan, 277-8577
Actively Recruiting
41
Hokkaido University Hospital
Sapporo, Hokkaido, Japan, 060-8648
Actively Recruiting
42
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan, 920
Actively Recruiting
43
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan, 104-0045
Actively Recruiting
44
Wakayama Medical University Hospital
Wakayama, Japan, 641-8510
Actively Recruiting
45
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea, 10408
Actively Recruiting
46
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea, 16247
Actively Recruiting
47
Chonnam National University Hwasun Hospital
Hwasun-gun, Jeonranamdo, South Korea, 58128
Actively Recruiting
48
Seoul National University Hospital
Seoul, Korea, South Korea, 03080
Actively Recruiting
49
Asan Medical Center
Seoul, Korea, South Korea, 05505
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here